These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8334769

  • 1. [Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis].
    Watanabe T, Yamamoto T, Saito T, Sugano M, Tsukamoto T.
    Rinsho Shinkeigaku; 1993 Jan; 33(1):15-20. PubMed ID: 8334769
    [Abstract] [Full Text] [Related]

  • 2. [Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases].
    Watanabe T, Shimoji S, Sugiyama Y, Tsukamoto T, Yamamoto T.
    Rinsho Shinkeigaku; 1995 Jun; 35(6):611-6. PubMed ID: 8521635
    [Abstract] [Full Text] [Related]

  • 3. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK.
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [Abstract] [Full Text] [Related]

  • 4. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
    Smith D.
    J Neurol Sci; 2004 Aug 15; 223(1):73-9. PubMed ID: 15261565
    [Abstract] [Full Text] [Related]

  • 5. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL.
    N Engl J Med; 1983 Jan 27; 308(4):173-80. PubMed ID: 6294517
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of systemic diseases with pulse cyclophosphamide: 15 cases].
    Amoura Z, Choukroun G, Royer I, Gayraud M, Guillevin L.
    Ann Med Interne (Paris); 1990 Jan 27; 141(5):416-20. PubMed ID: 2256584
    [Abstract] [Full Text] [Related]

  • 7. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Sénéchal O, Vermersch P.
    J Neurol Sci; 2004 Mar 15; 218(1-2):73-7. PubMed ID: 14759636
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL.
    Neurology; 1988 Jul 15; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [Abstract] [Full Text] [Related]

  • 9. [The course and prognosis of mesangioproliferative glomerulonephritis].
    Shilov EM, Tareeva IE, Ivanov AA, Troepol'skaia OV, Krasnova TN, Varshavskiĭ VA, Proskurneva EP, Ivanova LV, Khudova IIu, Miroshnichenko NG.
    Ter Arkh; 2002 Jul 15; 74(6):11-8. PubMed ID: 12136475
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
    Perini P, Gallo P.
    J Neurol; 2003 Jul 15; 250(7):834-8. PubMed ID: 12883926
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM, Carter JL, Hafler DA, Weiner HL.
    Riv Neurol; 1987 Jul 15; 57(2):88-91. PubMed ID: 3039645
    [Abstract] [Full Text] [Related]

  • 14. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
    J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L, Perini P, Calabrese M, Gallo P.
    Neurol Sci; 2009 Oct 15; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.